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Background: Redox-active iron, a catalyst in the production of hydroxyl radicals via the Fenton reaction,
is one of the key participants in ROS-induced tissue injury and general inﬂammation. According to our
recent ﬁndings, an excess of tissue iron is involved in several airway-related pathologies such as nasal
polyposis and asthma.
Objective: To examine the anti-inﬂammatory properties of a newly developed speciﬁc iron–chelating
complex, Zn/GaDFO, in a mouse model of asthma.
Materials and methods: Asthma was induced in BALBc mice by ovalbumin, using aluminum hydroxide as
an adjuvant. Mice were divided into four groups: (i) control, (ii) asthmatic and sham-treated, (iii)
asthmatic treated with Zn/GaDFO [intra-peritoneally (i/p) and intra-nasally (i/n)], and (iv) asthmatic
treated with Zn/GaDFO, i/n only. Lung histology and cytology were examined. Biochemical analysis of
pulmonary levels of ferritin and iron-saturated ferritin was conducted.
Results: The amount of neutrophils and eosinophils in bronchoalveolar lavage ﬂuid, goblet cell
hyperplasia, mucus secretion, and peri-bronchial edema, showed markedly better values in both
asthmatic-treated groups compared to the asthmatic non-treated group. The non-treated asthmatic
group showed elevated ferritin levels, while in the two treated groups it returned to baseline levels.
Interestingly, i/n-treatment demonstrated a more profound effect alone than in a combination with i/p
injections.
Conclusion: In this mouse model of allergic asthma, Zn/GaDFO attenuated allergic airway inﬂamma-
tion. The beneﬁcial effects of treatment were in accord with iron overload abatement in asthmatic lungs
by Zn/GaDFO. The ﬁndings in both cellular and tissue levels supported the existence of a signiﬁcant
anti-inﬂammatory effect of Zn/GaDFO.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Asthma is a chronic inﬂammation of the lungs in which the
airways (bronchi) are reversibly narrowed. Asthma affects 7% of
the population, 300 million people worldwide. During attacks
(exacerbations), the smooth muscle cells in the inﬂamed bronchi
constrict and the airways swell, causing breathing difﬁculties. The
frequency of acute asthmatic attacks depends on asthma severity.
Acute asthma exacerbations cause 4000 deaths per year in the
USA. Attacks may be prevented by avoiding triggering factors and
by medical treatment. Drugs commonly used for treatment of
acute attacks are inhaled β2 agonists. In severe cases, drugs are
used for long-term prevention. They include inhaled corticoster-
oids, which may be supplemented with long-acting β2-agonists
when necessary, leukotriene antagonists, which are less effective
than corticosteroids but have no side effects, and monoclonal
antibodies such as mepolizumab and omalizumab.
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According to several reports, asthma attacks are associated
with aggravation of the inﬂammatory condition and with a
signiﬁcant increase in the production of reactive oxygen-derived
species (ROS), including free radicals (FR) [1].
Iron is an essential element in all tissues and cells. However, an
excess of labile iron is deleterious and causes cellular injury. This
two-phase behavior is also shared by ROS – at low levels it
functions as a beneﬁcial signaling species, but at higher concen-
trations, speciﬁc FRs may cause damage. Labile, redox-active iron
serves as a catalyst in the production of hydroxyl radicals via the
Fenton reaction, and is therefore one of the key participants in
ROS-induced injury and development of an inﬂammatory condi-
tion [2]. In a well-protected cell, 95–98% of the iron is stored in
ferritin, the major iron storage and detoxifying protein, keeping
labile redox-active iron at sub-micromolar levels. An increase in
the concentration of cellular ferritin indicates that an initial event
has occurred, during which the cellular levels of redox-active iron
had increased, but were subsequently detoxiﬁed by the additional
ferritin [3,4]. Various pathologic conditions, including asthma,
have been proposed as being associated with such an increase in
the cellular levels of iron and ferritin, presumably in response to a
rise in ROS production [5]. This increase may stem as well from
asthma-induced up-regulation of divalent metal transporter-1
(DMT1), transferring Fe2þ from extracellular matrix into the cell [6].
Rise in iron concentration leads to enhanced production of cellular
ferritin to store this iron in a catalytically less reactive state.
Asthma is known to be associated with a severe form of
another human pathology, nasal polyposis (NP) [7]. The role of
labile iron redistribution in the development of the inﬂammatory
process and in the pathogenesis of NP was suggested in our recent
report [8]. We detected a signiﬁcant increase in ferritin and
ferritin-bound iron in nasal polyps from asthmatic patients. This
increase was accompanied by an up-regulation of the protein
carbonyls content (PCC), an oxidative stress marker, and a decrease
in the concentrations of methionine-centered redox cycle proteins,
which usually protect the cell against ROS-induced injury and,
therefore, against inﬂammation.
In 1991, the idea of a “push-and-pull” mechanism to scavenge
redox-active transition metals was suggested by Chevion [9].
He proposed that metal chelators, such as desferrioxamine (DFO),
are able to tightly bind redox active metals such as iron and copper,
thus preventing their participation in the ROS-producing Fenton
reaction, diminishing therefore the level of oxidative damage [10]
and even reducing production of pro-inﬂammatory cytokines [11].
While DFO is bound with zinc, gallium, or other redox-inactive
metals, these metals are easily released in the presence of iron due to
a higher DFO afﬁnity to iron, being “pushed away”, thus leading to
iron displacement, and diverting the site of FR attack. The usage of
zinc–DFO and gallium–DFO complexes has additional advantages,
since anti-inﬂammatory, and even speciﬁcally anti-asthmatic, effect
of these metals has been reported [12–16].
DFO by itself is a relatively large, randomly oriented non-polar
molecule, that does not easily penetrate cells, and provides only a
minimal protection against FR damage [17]. However, when
complexed with gallium or with zinc, it assumes a well-deﬁned
compact structure, likely enhancing its ability to inﬁltrate cell
membranes. The pathophysiological effects (e.g. chemical or alkali
burns and cardiac ischemia-reperfusion injury) of these complexes
were tested in various animal models [9,17–21].
Animal models mimicking the pathophysiology of human
asthma are important tools for studying the mechanisms of
AllerGen-induced asthma, airway hyper-responsiveness (AHR),
airway inﬂammation, and reversible airway obstruction (National
Heart, Lung, and Blood Institute. Update 2009. Global Initiative for
Asthma Global strategy for asthma management and prevention.
NHLBI/WHO workshop report). Several reports [22–24] have used
AllerGen-sensitized mice to describe the roles that cells and
cytokines play in the development of AHR, demonstrating the
usefulness and acceptability of this animal model. The BALB/c
strain of mice, known to be highly susceptible to asthma induction
protocols [25–27], serve as the gold standard for studying inﬂam-
matory and bronchial hyper-reactive airways.
The objective of the current study was to evaluate the effect of
Zn/GaDFO complexes as speciﬁc iron chelators in the treatment
of asthma.
Materials and methods
Complex preparation
To prepare zinc-/gallium-complex with desferrioxamine, a 10
millimoles solution of desferrioxamine mesylate was mixed with
equal volume of ZnCl2 or GaCl3 10 millimoles solution and titrated
to pH 7.4. To form the complex, the mixture was heated to 45 1C
for 30min. The metal:DFO ratio in the complex was 1.0:1.0. A 3:1
mixture of ZnDFO and GaDFO was applied.
Model description
All the experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of Technion – Israel
Institute of Technology, Haifa, conforming to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH, Publication 85-23, revised 1996). The
experiments were performed using an animal model of asthma
induced by ovalbumin (OVA) sensitization [28]. BALB/c female 8 w.
o. mice, purchased from Harlan, Israel, were divided into 4 groups
(n¼8): (1) control; (2) asthmatic, sham-treated; (3) asthmatic,
treated with Zn/GaDFO complex intra-peritoneally (i/p) and
intra-nasally (i/n); (4) asthmatic treated with Zn/GaDFO com-
plex, i/n only. The dose and pattern of administration were based
on previous experiments performed by Chevion [9,18,29]. The
animals were sensitized to ovalbumin by intra-peritoneal 100 ml
injection (10 mg ovalbumin and 3mg Al(OH)3 in 0.9% saline) on
days 0, 7, and 14. The mice were further sensitized with intra-nasal
instillations of OVA (50 ml) on days 17, 19, 20, and 23. Group
3 received prophylactic treatment by 2 i/p injections (100 ml each;
1mg of Zn/GaDFO complex per kg body weight in saline buffer)
5 days and 1 day before the ﬁrst sensitization. Subsequently, the
i/p injections containing only 1/3 of the dose (0.3mg/kg) were
given one day before and one day after the OVA sensitization,
while a dose of 1mg/kg weight was given on the day of sensitiza-
tion. From day 15, the complex was given i/n.
Group 4 received 5mg/kg of Zn/GaDFO i/n only, according to
the same administration pattern. Animals in the control non-
asthmatic group received saline injections and instillations, using
the same regime. At the end of the experiments, Day 24, the
animals were sacriﬁced with a ketamine/xylazine mixture.
Biochemical parameters
The lung samples were homogenized in lysis buffer using a
Teﬂon homogenizer. Ferritin concentration was quantiﬁed using
an indirect ‘sandwich’ ELISA assay, accordingly to the procedure
developed previously in our laboratory [30]. Ferritin was immu-
noprecipitated and ferritin-bound iron was measured as pre-
viously described [31].
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Histology parameters
BAL using 1ml of saline solution was performed immediately
after sacriﬁce. BAL ﬂuid on cytospin slides was ﬁxed and stained
with Diff-Quick, and counted under a light microscope. Following
lavage, the lungs were excised, ﬁlled with a 4% paraformaldehyde
solution, and sliced longitudinally into 3 parts. The middle third
was embedded in parafﬁn, randomly sliced, and stained with
eosin–hematoxylin. The intensity of the peribronchial and peri-
vascular cellular inﬁltration and mucous content was assessed
(n¼5 per group).
Periodic Acid Schiff (PAS) staining was used to assess epithelial
cells metaplasia, and Masson’s trichrome staining was used to
evaluate the presence of ﬁbrous connective tissue.
Statistical analysis
The data was analyzed using repeated one-way ANOVA fol-
lowed by the Scheffe post-hoc test for multiple comparisons (with
α¼0.05). Differences between mean values with pr0.05 were
considered statistically signiﬁcant.
Results
Thirty two mice were studied, four groups of 8 mice.
The concentrations of ferritin in the lungs are shown in Fig. 1A.
The baseline ferritin concentration, observed in the control lungs,
was 0.1770.02 mg ferritin/mg protein. A signiﬁcant increase was
found in asthmatic (non-treated) lungs, at 0.4570.06 mg/mg
protein. In i/n treated lungs, a value of 0.2870.04 mg ferritin/mg
protein was observed, and in the lungs treated by both i/p and i/n,
ferritin concentration was down-regulated to a level only slightly
above the control group.
Although the levels of ferritin saturation with iron (Fig. 1B) in
the lungs of asthmatic and control mice were similar, the total
amount of ferritin-bound iron (FBI) was 2.7 times higher in
asthmatic mice lungs, due to a higher ferritin concentration
(Fig. 1A). Treatment with Zn/GaDFO, either i/pþ i/n, or i/n only,
decreased both the general amount of ferritin and the level of iron
saturation. There were no signiﬁcant differences in FBI between
the treated groups.
The amounts of eosinophils and neutrophils in BAL ﬂuid are
shown in Fig. 2. The eosinophil count (Fig. 2A) from the control
group was the lowest at 2.070.5104 cells/ml, but asthma
caused 5.5 fold increase (po0.05). No statistically signiﬁcant
differences were found between asthmatic mice lungs and lungs
from the i/pþ i/n group. However, sub-baseline levels were found
in the i/n only group.
Neutrophil count (Fig. 2B) in control mice was 6.872.3104
cells/ml. In non-treated asthmatic mice, a 6.3-fold increase was
detected (po0.05). In the asthmatic-treated group 3 (Zn/GaDFO,
i/pþ i/n), the value decreased to 29.874.3104 cells/ml, but was
still signiﬁcantly above the control value (po0.05). In i/n-only
treated mice, neutrophils concentration decreased to slightly
below baseline, 2.070.4104 cells/ml, which was signiﬁcantly
different (po0.05) from the values found in asthmatic sham-
treated and in the i/pþ i/n-treated asthmatic mice.
Comparing mucous content values (Table 1), we found that
both methods of treatment were able to reduce mucous levels to
the baseline values.
Histological parameters are shown in Fig. 3. The histological
score was based on integer values scaled from 0 to 3. In general,
the different experimental groups showed congruent results for
peri-bronchial staining for ﬁbrous connective tissue (C). Similar to
the previous results, the asthmatic group received the highest
average score at 2.5, while the control level was 0. Both modes
of treatment succeeded in decreasing the asthma-associated
parameters by at least 1.5-fold, however, the i/n treatment showed
a more profound effect than the i/pþ i/n treatment. Representative
slides of PAS staining demonstrating the effect of Zn/GaDFO on
epithelial cell metaplasia are shown in Fig. 4.
Discussion
The present study focused on the role of iron and iron-catalyzed
oxidative injury in the asthmatic inﬂammatory process. Recently,
we showed that iron re-distribution plays an important role in the
NP inﬂammatory pathway, and that this effect was exaggerated in
asthmatics [8]. In the current study, we sequestrated iron using Zn/
GaDFO, a speciﬁc iron chelator developed in our laboratory, and
tested its effects on several asthma-associated parameters using a
classic murine OVA model.
Maintenance of iron homeostasis is of utmost importance to the
physiology and pathophysiology of the respiratory system. Local iron
deﬁciency can impair the growth and proliferation of cells responsible
for inﬂammatory response and tissue repair [32,33]. Cellular iron
homeostasis is maintained through post-transcriptional regulation of
Fig. 1. The concentration of ferritin (A) and Fe-saturated ferritin (B) in mice lungs.
Ferritin concentration was quantiﬁed using an indirect ‘sandwich’ ELISA assay in
accordance with a procedure developed previously in our laboratory [30]. ELISA 96-
well microplates were pre-coated with goat anti-rat L-ferritin antibody. Rabbit
anti-rat H-ferritin was used as the secondary antibody. Plates were treated with
goat anti-rabbit IgG conjugated with β-galactosidase. Chlorophenol Red-β-D-
Galactopyranoside was then added and the plates were analyzed using a micro-
plate reader with test (570 nm) and reference (630 nm) ﬁlters. Ferritin-bound iron
was measured as follows. In order to reach a concentration of 2mg ferritin/1ml,
several samples from each group were pooled together. Ferritin was immune-
precipitated using a mixture of anti-H and anti-L ferritin antibodies, developed in
our lab. The precipitate was dissolved in nitric acid, and iron content was
determined spectrophotometrically with batho-phenanthroline bi-sulfonate, using
535 nm ﬁlters. Means7SE are shown. n Denotes po0.05 vs. the control; # denotes
po0.05 vs. the asthmatic non-treated group.
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ferritin and transferrin receptor (TfR) via iron regulatory proteins (IRP).
In the mRNA of ferritin and TfR, there are iron-responsive elements
(IRE) that can bind or release the IRPs, thereby blocking or enabling
translation and protein synthesis [34]. Inﬂammatory mediators, such
as hydrogen peroxide and nitric oxide, may also regulate IRP activity in
order to increase ferritin and TfR synthesis during inﬂammatory
processes. In fact, ferritin accumulation and inﬂammation have been
linked by several published reports [35,36]. Understanding the rela-
tionship between iron homeostasis and inﬂammation is of great
importance, especially since the respiratory tract is open to the
external environment and constantly exposed to potentially inﬂam-
matory stimuli [37]. The therapeutic effect of DFO is based on a
chelation of labile, redox-active iron, directly associated with an
inﬂammatory process.
Treatment with Zn/GaDFO complexes via both administra-
tion methods decreased the level of ferritin and the level of FBI in
asthmatic mice lungs (Fig. 1). However, the treatment by intranasal
Table 1
Mucous content in mice lungs.
Group Mucous content value
Asthma 0.8 7 0.2*
Control 0
AsthmaþZn/GaDFO i/n 0
Asthma þ Zn/Ga–DFO i/pþ i/n 0
Average7ME is shown.
* Denotes po0.05 vs. the control.
Fig. 3. Histology scores of mice lungs from the experimental groups: peri-
broncheal inﬁltrate (A), PAS (B) and Mason’s trichrome (C) staining. Following
lung lavage, the lungs were excised and ﬁlled paraformaldehyde and sliced
longitudinally into 3 parts. The middle third was embedded in parafﬁn, randomly
sliced, and stained with eosin-hematoxylin. The intensity of the peribronchial and
perivascular cellular inﬁltration was assessed semi-quantitatively by light micro-
scopy on a 0–3 scale as follows: 0¼no, or practically no inﬂammatory cells; 1¼a
narrow rim of inﬂammatory cells surrounding most of the bronchioles/blood
vessels, best visualized by high power ﬁled; 2¼a rim of inﬂammatory cells 3–4
cells thick, surrounding most of the bronchioles/blood vessels; and 3¼a prominent
rim of inﬂammatory cells, 5 or more cells thick, surrounding most of the
bronchioles/blood vessels. Periodic acid Schiff (PAS) staining was used to assess
metaplasia of epithelial cells, and Masson’s trichrome staining was used to evaluate
the presence of ﬁbrous connective tissue. Both were scored as follows: 0 – none,
1 – mild, 2 – moderate, 3 – signiﬁcant [47]. Histological assessment was performed
by an independent pathologist, blinded to the study groups. Means7SE is shown.
n Denotes po0.05 vs. the control; # denotes po0.05 vs. the asthmatic non-
treated group.
Fig. 2. The amount of eosinophils (A) and neutrophils (B) in mice BAL ﬂuid.
To estimate the anti-inﬂammatory effect of the treatment provided, the amounts
of eosinophils and neutrophils in bronchoalveolar lavages (BAL) were measured.
BAL using 1ml of a buffered saline solution was performed immediately after the
ketamine/xylazine injection. BAL ﬂuid on cytospin slides was ﬁxed and stained
with diff-quick. Differential cell counts were obtained under a light microscope.
Mean7SE is shown. n Denotes po0.05 vs. the control; # denotes po0.05 vs. the
asthmatic sham-treated group.
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instillations alone demonstrated a more profound therapeutic
effect. Since the allergenic effect of OVA extends through the
whole organism [38], we expected a general inﬂammation-
associated increase in the concentration of labile iron. Thus, only
a part of Zn/GaDFO injected i/p reached the site of inﬂammation
in active form without iron ion bound. On the other hand, while
the complex, from the beginning of the treatment, was adminis-
tered by intranasal instillation, being applied almost directly on
the site of inﬂammation, the pathogenic local iron accumulation in
the lungs was immediately reduced, and therapeutic effect was
signiﬁcantly improved.
Kruzel et al. showed that lactoferrin (LTF), a pleiotropic 80-kDa
glycoprotein with iron-binding properties, exhibited a potent anti-
allergic effect [39]. Bournazou et al. showed that LTF acted as a
powerful speciﬁc inhibitor of eosinophil migration [40]. Our
results (Fig. 2) corroborate these ﬁndings. However, only local
treatment via intra-nasal instillations decreased the level of
eosinophils in the BAL of asthmatic mice lungs.
Neutrophil levels in BAL ﬂuid was reduced by both methods of
administration. Consistently with our previous observations, intra-
nasal instillations demonstrated a much higher efﬁcacy in reducing
this parameter compared to systemic treatment by i/p injections.
Both methods of treatment for clearing asthma-induced respiratory
mucous were successful, eliminating it completely.
The same trend was observed in all parameters of the three
histology scores (Fig. 3). A pivotal role of ROS in asthma-induced
lung remodeling was reported [41]. Chelation of labile iron,
involved in ROS formation, by Zn/GaDFO complex did not
completely abolish asthma-induced lung remodeling, but reduced
it signiﬁcantly, and, similar to the results observed in the BAL
experiments, intra-nasal instillations were much more effective
than i/p injections. In contrast to iron accumulation, tissue
remodeling and white blood cell inﬁltration are local processes,
and direct application of the drug in situ is markedly more
effective than systemic treatment. Comparing the results of two
assays employing an OVA-induced murine model of asthma, one
using the Zn/GaDFO complex, a potentially novel anti-asthmatic
drug, and one using 2-Methoxyestradiol (ME), a steroidal anti-
asthmatic compound, one may conclude that the novel complex
exerts an equivalent, if not a better effect as ME [42]. However, in
the current study, animals were subjected to a prophylactic
treatment, while ME was administered after the onset of asthma.
In addition to their effects together with DFO, zinc and gallium
by themselves bear anti-oxidant and anti-inﬂammatory potentials
[12–16], with reports that zinc possibly possess direct anti-
asthmatic effects as well [43,44]. Thus, the newly suggested Zn/
GaDFO complex probably acts via the combination of three
different mechanisms – anti-oxidative, anti-inﬂammatory, and
iron–chelating – simultaneously. These ﬁndings are in accord with
a line of previous publications, showing a beneﬁcial effect of Zn/
GaDFO complex on several organs, exposed to different kinds of
stress, such as heart and retina under ischemia-reperfusion con-
ditions, and chemically injured cornea or lens under hyperbaric
oxygen conditions. In these applications, the complex has been
demonstrated to reduce the levels of malondialdehyde and DHBA
(the indicators of lipid peroxidation and hydroxyl radical forma-
tion, respectively), and generally increased a systemic antioxidant
status [20,21,29,45].
According to the results by Obolensky et al. [46], the compo-
nents of the complex, Zn and DFO, when administered alone,
showed a lesser, partial effect, while the conclusion about the
synergy, existing between zinc and DFO in the Zn/GaDFO
complex can be drawn.
We conclude that Zn/GaDFO complex has a signiﬁcant
potential as an anti-asthmatic drug. However, several assays are
required in order to clarify its mechanism of action, to study its
effects in humans, and to investigate its systemic effects.
Acknowledgments
This research was supported by research grants from the Dr.
Avraham Moshe and Pepka Bergman Memorial Fund, by the
GIF-German-Israeli Foundation for Scientiﬁc Research and Develop-
ment (GIF 1061-59.2/2008), and by the ISF-Israel Science Foundation
(ISF 489/12).
References
[1] P.A. Henricks, F.P. Nijkamp, Reactive oxygen species as mediators in asthma,
Pulmonary Pharmacology & Therapeutics 14 (2001) 409–420, http://dx.doi.
org/10.1016/j.redox.2014.06.009 11782121.
[2] J. Carrier, E. Aghdassi, I. Platt, J. Cullen, J.P. Allard, Effect of oral iron
supplementation on oxidative stress and colonic inﬂammation in rats with
Fig. 4. Representative slides of PAS-stained lungs: (A) control; (B) asthmatic; (C) Zn/GaDFO i/pþ i/n-treated.
H. Bibi et al. / Redox Biology 2 (2014) 814–819818
induced colitis, Alimentary Pharmacology & Therapeutics 15 (2001) 1989–-
1999, http://dx.doi.org/10.1016/j.redox.2014.06.009 11736731.
[3] K.J. Hintze, E.C. Theil, Cellular regulation and molecular interactions of the
ferritins, Cellular and Molecular Life Sciences: CMLS 63 (2006) 591–600, http:
//dx.doi.org/10.1016/j.redox.2014.06.009 16465450.
[4] X. Liu, E.C. Theil, Ferritin as an iron concentrator and chelator target, Annals of
the New York Academy of Sciences 1054 (2005) 136–140, http://dx.doi.org/
10.1016/j.redox.2014.06.009 16339659.
[5] M.K. Narula, G.K. Ahuja, J. Whig, A.P. Narang, R.K. Soni, Status of lipid
peroxidation and plasma iron level in bronchial asthmatic patients, Indian
Journal of Physiology and Pharmacology 51 (2007) 289–292 18341227.
[6] X. Wang, Y. Wu, J.G. Stonehuerner, L.A. Dailey, J.D. Richards, et al., Oxidant
generation promotes iron sequestration in BEAS-2B cells exposed to asbestos,
American Journal of Respiratory Cell and Molecular Biology 34 (2006) 286–-
292, http://dx.doi.org/10.1016/j.redox.2014.06.009 16272461.
[7] J.R. Moloney, R.T. Oliver, HLA antigens, nasal polyps and asthma, Clinical
Otolaryngology and Allied Sciences 5 (1980) 183–189, http://dx.doi.org/
10.1016/j.redox.2014.06.009 7408219.
[8] V. Vinokur, E. Berenshtein, M.M. Chevion, R. Eliashar, Iron homeostasis and
methionine-centred redox cycle in nasal polyposis, Free Radical Research 45
(2011) 366–373 21110782.
[9] M. Chevion, Protection against free radical-induced and transition metal-
mediated damage: the use of “pull” and “push” mechanisms, Free Radical
Research Communications 12–13 (2) (1991) 691–696 2060841.
[10] S. Schaal, I. Beiran, H. Rozner, I. Rubinstein, M. Chevion, et al., Desferrioxamine
and zinc-desferrioxamine reduce lens oxidative damage, Experimental Eye
Research 84 (2007) 561–568, http://dx.doi.org/10.1016/j.redox.2014.06.009
17239855.
[11] D. Vlahakos, N. Arkadopoulos, G. Kostopanagiotou, S. Siasiakou, L. Kaklamanis,
et al., Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 pro-
duction, ameliorates sepsis inﬂammatory response syndrome, and confers
renoprotection after acute hepatic ischemia in pigs, Artiﬁcial Organs 36 (2012)
400–408, http://dx.doi.org/10.1016/j.redox.2014.06.009 22187937.
[12] S. Bao, M.J. Liu, B. Lee, B. Besecker, J.P. Lai, et al., Zinc modulates the innate
immune response in vivo to polymicrobial sepsis through regulation of
NF-kappaB, American Journal of Physiology: Lung Cellular and Molecular
Physiology 298 (2010) L744–L754, http://dx.doi.org/10.1016/j.
redox.2014.06.009 20207754.
[13] S. Betoulle, J.C. Etienne, G. Vernet, in vivo and in vitro modulation of carp
(Cyprinus carpio L.) phagocyte oxidative burst activity by gallium, Journal of
Toxicology and Environmental Health, Part A 65 (2002) 603–615, http://dx.
doi.org/10.1016/j.redox.2014.06.009 11991633.
[14] C.R. Chitambar, Medical applications and toxicities of gallium compounds,
International Journal of Environmental Research and Public Health 7 (2010)
2337–2361, http://dx.doi.org/10.1016/j.redox.2014.06.009 20623028.
[15] A.H. Shankar, A.S. Prasad, Zinc and immune function: the biological basis of
altered resistance to infection, American Journal of Clinical Nutrition 68 (1998)
447S–463S 9701160.
[16] Z. Wu, S.D. Holwill, D.B. Oliveira, Desferrioxamine modulates chemically
induced T helper 2-mediated autoimmunity in the rat, Clinical and Experi-
mental Immunology 135 (2004) 194–199, http://dx.doi.org/10.1016/j.
redox.2014.06.009 14738445.
[17] M. Chevion, A site-speciﬁc mechanism for free radical induced biological
damage: the essential role of redox-active transition metals, Free Radical
Biology & Medicine 5 (1988) 27–37, http://dx.doi.org/10.1016/j.redox.2014.06.009
3075945.
[18] E. Banin, Y. Morad, E. Berenshtein, A. Obolensky, C. Yahalom, et al., Injury induced
by chemical warfare agents: characterization and treatment of ocular tissues
exposed to nitrogen mustard, Investigative Ophthalmology & Visual Science 44
(2003) 2966–2972, http://dx.doi.org/10.1016/j.redox.2014.06.009 12824239.
[19] M. Chevion, L. Chuang, J. Golenser, Effects of zinc-desferrioxamine on
Plasmodium falciparum in culture, Antimicrobial Agents and Chemotherapy
39 (1995) 1902–1905, http://dx.doi.org/10.1016/j.redox.2014.06.009 7486946.
[20] M. Karck, S. Tanaka, E. Berenshtein, C. Sturm, A. Haverich, et al., The push-and-
pull mechanism to scavenge redox-active transition metals: a novel concept in
myocardial protection, Journal of Thoracic and Cardiovascular Surgery 121
(2001) 1169–1178, http://dx.doi.org/10.1016/j.redox.2014.06.009 11385385.
[21] Y. Morad, E. Banin, E. Averbukh, E. Berenshtein, A. Obolensky, et al., Treatment
of ocular tissues exposed to nitrogen mustard: beneﬁcial effect of zinc
desferrioxamine combined with steroids, Investigative Ophthalmology &
Visual Science 46 (2005) 1640–1646, http://dx.doi.org/10.1016/j.redox.2014.06.009
15851563.
[22] P.J. Barnes, New concepts in the pathogenesis of bronchial hyperresponsive-
ness, Agents and Actions Supplements 21 (1987) 225–237 3314413.
[23] J. Bousquet, P. Chanez, J.Y. Lacoste, G. Barnéon, N. Ghavanian, et al., Eosino-
philic inﬂammation in asthma, New England Journal of Medicine 323 (1990)
1033–1039, http://dx.doi.org/10.1016/j.redox.2014.06.009 2215562.
[24] R. Djukanović, W.R. Roche, J.W. Wilson, C.R. Beasley, O.P. Twentyman, et al.,
Mucosal inﬂammation in asthma, American Review of Respiratory Disease 142
(1990) 434–457, http://dx.doi.org/10.1016/j.redox.2014.06.009 2200318.
[25] K. Shinagawa, M. Kojima, Mouse model of airway remodeling: strain differ-
ences, American Journal of Respiratory and Critical Care Medicine 168 (2003)
959–967, http://dx.doi.org/10.1016/j.redox.2014.06.009 12857720.
[26] K. Takeda, A. Haczku, J.J. Lee, C.G. Irvin, E.W. Gelfand, Strain dependence of
airway hyperresponsiveness reﬂects differences in eosinophil localization in
the lung, American Journal of Physiology: Lung Cellular and Molecular
Physiology 281 (2001) L394–L402 11435214.
[27] C. Taube, A. Dakhama, E.W. Gelfand, Insights into the pathogenesis of asthma
utilizing murine models, International Archives of Allergy and Immunology
135 (2004) 173–186, http://dx.doi.org/10.1016/j.redox.2014.06.009 15375327.
[28] T.T. Kung, H. Jones, G.K. Adams 3rd, S.P. Umland, W. Kreutner, et al.,
Characterization of a murine model of allergic pulmonary inﬂammation,
International Archives of Allergy and Immunology 105 (1994) 83–90, http:
//dx.doi.org/10.1016/j.redox.2014.06.009 8086833.
[29] E. Banin, E. Berenshtein, N. Kitrossky, J. Pe’er, M. Chevion, Gallium-
desferrioxamine protects the cat retina against injury after ischemia and
reperfusion, Free Radical Biology & Medicine 28 (2000) 315–323, http://dx.
doi.org/10.1016/j.redox.2014.06.009 10699741.
[30] E. Berenshtein, B. Vaisman, C. Goldberg-Langerman, N. Kitrossky, A.M. Konijn,
et al., Roles of ferritin and iron in ischemic preconditioning of the heart,
Molecular and Cellular Biochemistry 234–235 (2002) 283–292.
[31] U.A. Nilsson, M. Bassen, K. Sävman, I. Kjellmer, A simple and rapid method for
the determination of “free” iron in biological ﬂuids, Free Radical Research 36
(2002) 677–684, http://dx.doi.org/10.1016/j.redox.2014.06.009 12180193.
[32] T. Hirata, P.B. Bitterman, J.F. Mornex, R.G. Crystal, Expression of the transferrin
receptor gene during the process of mononuclear phagocyte maturation, Journal
of Immunology (Baltimore, MD: 1950) 136 (1986) 1339–1345 3003194.
[33] F. Mateos, J.H. Brock, J.L. Pérez-Arellano, Iron metabolism in the lower
respiratory tract, Thorax 53 (1998) 594–600, http://dx.doi.org/10.1016/j.
redox.2014.06.009 9797761.
[34] R.S. Eisenstein, Iron regulatory proteins and the molecular control of mam-
malian iron metabolism, Annual Review of Nutrition 20 (2000) 627–662, http:
//dx.doi.org/10.1016/j.redox.2014.06.009 10940348.
[35] W. Wang, M.A. Knovich, L.G. Coffman, F.M. Torti, S.V. Torti, Serum ferritin:
past, present and future, Biochimica et Biophysica Acta 1800 (2010) 760–769,
http://dx.doi.org/10.1016/j.redox.2014.06.009 20304033.
[36] R.K. Watt, The many faces of the octahedral ferritin protein, Biometals:
An International Journal on the Role of Metal Ions in Biology, Biochemistry,
and Medicine 24 (2011) 489–500, http://dx.doi.org/10.1016/j.
redox.2014.06.009 21267633.
[37] E.L. Kwak, D.A. Larochelle, C. Beaumont, S.V. Torti, F.M. Torti, Role for NF-kappa
B in the regulation of ferritin H by tumor necrosis factor-alpha, Journal of
Biological Chemistry 270 (1995) 15285–15293, http://dx.doi.org/10.1016/j.
redox.2014.06.009 7797515.
[38] Y.N. Park, Y.J. Lee, J.H. Choi, M. Jin, J.H. Yang, et al., Alleviation of OVA-induced
airway inﬂammation by ﬂowers of Inula japonica in a murine model of
asthma, Bioscience, Biotechnology, and Biochemistry 75 (2011) 871–876,
http://dx.doi.org/10.1016/j.redox.2014.06.009 21597181.
[39] M.L. Kruzel, A. Bacsi, B. Choudhury, S. Sur, I. Boldogh, Lactoferrin decreases
pollen antigen-induced allergic airway inﬂammation in a murine model of
asthma, Immunology 119 (2006) 159–166, http://dx.doi.org/10.1016/j.
redox.2014.06.009 16800860.
[40] I. Bournazou, K.J. Mackenzie, R. Dufﬁn, A.G. Rossi, C.D. Gregory, Inhibition of
eosinophil migration by lactoferrin, Immunology and Cell Biology 88 (2010)
220–223 19918259.
[41] I. Rahman, W. MacNee, Oxidative stress and regulation of glutathione in lung
inﬂammation, European Respiratory Journal 16 (2000) 534–554, http://dx.doi.
org/10.1016/j.redox.2014.06.009 11028671.
[42] S. Huerta-Yepez, G.J. Baay-Guzman, R. Garcia-Zepeda, R. Hernandez-Pando,
M.I. Vega, et al., 2-Methoxyestradiol (2-ME) reduces the airway inﬂammation
and remodeling in an experimental mouse model, Clinical Immunology
(Orlando, FL) 129 (2008) 313–324, http://dx.doi.org/10.1016/j.redox.2014.06.009
18793875.
[43] C. Lang, C. Murgia, M. Leong, L.W. Tan, G. Perozzi, et al., Anti-inﬂammatory
effects of zinc and alterations in zinc transporter mRNA in mouse models of
allergic inﬂammation, American Journal of Physiology. Lung Cellular and
Molecular Physiology 292 (2007) L577–L584 17085522.
[44] A.Q. Truong-Tran, R.E. Rufﬁn, P.S. Foster, A.M. Koskinen, P. Coyle, et al., Altered
zinc homeostasis and caspase-3 activity in murine allergic airway inﬂamma-
tion, American Journal of Respiratory Cell and Molecular Biology 27 (2002)
286–296, http://dx.doi.org/10.1016/j.redox.2014.06.009 12204890.
[45] S. Schaal, I. Beiran, E. Bormusov, M. Chevion, A. Dovrat, Zinc-desferrioxamine
reduces damage to lenses exposed to hyperbaric oxygen and has an ameli-
orative effect on catalase and Na, K-ATPase activities, Experimental Eye
Research 84 (2007) 455–463, http://dx.doi.org/10.1016/j.redox.2014.06.009
17174302.
[46] A. Obolensky, E. Berenshtein, M. Lederman, B. Bulvik, R. Alper-Pinus, et al.,
Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse
model of retinitis pigmentosa, Free Radical Biology & Medicine 51 (2011)
1482–1491, http://dx.doi.org/10.1016/j.redox.2014.06.009 21824515.
[47] W.R. Henderson Jr., D.B. Lewis, R.K. Albert, Y. Zhang, W.J. Lamm, et al., The
importance of leukotrienes in airway inﬂammation in a mouse model of
asthma, Journal of Experimental Medicine 184 (1996) 1483–1494, http://dx.
doi.org/10.1016/j.redox.2014.06.009 8879219.
H. Bibi et al. / Redox Biology 2 (2014) 814–819 819
